$BMY Headlines Bristol-Myers guidance tops est
Post# of 94140
Posted On: 01/29/2016 12:54:15 PM
$BMY Headlines
Bristol-Myers guidance tops estimates 7:06 a.m. Jan. 28, 2016 - MarketWatch.com
Apple, Amazon headline crucial week for Wall Street quarterly results 9:30 a.m. Jan. 23, 2016 - Wallace Witkowski
10 biotech stocks to buy at ‘silly’ cheap prices 10:10 a.m. Jan. 16, 2016 - Michael Brush
Shire agrees to buy Baxalta for $32 billion 8:49 a.m. Jan. 11, 2016 - MarketWatch.com
GlaxoSmithKline buys Bristol-Myers HIV assets 4:33 a.m. Dec. 18, 2015 - MarketWatch.com
GlaxoSmithKline to buy Bristol-Myers's HIV assets 3:21 a.m. Dec. 18, 2015 - MarketWatch.com
Samsung's bet on biotech is test for heir apparent 5:37 p.m. Dec. 17, 2015 - MarketWatch.com
5 stocks to watch 12:18 p.m. Dec. 16, 2015 - The Trading Deck
Charting the S&P 500’s impending golden cross 11:05 a.m. Dec. 9, 2015 - Michael Ashbaugh
S&P 500 will creep up to 2,200 in 2016, J.P. Morgan says 7:01 a.m. Dec. 7, 2015 - Sara Sjolin
Bristol-Myers Squibb upgraded to buy from neutral at Guggenheim 12:04 p.m. Dec. 2, 2015 - Tomi Kilgore
Merck, J&J and Lilly shares climb after upgrades at Barclays 10:14 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers Squibb stock price target raised to $70 from $55 at Barclays 9:44 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers to buy Cardioxyl Pharmaceuticals 8:11 a.m. Nov. 2, 2015 - Ciara Linnane
Merck eyes acquisitions amid slump in biotech 12:12 p.m. Oct. 27, 2015 - MarketWatch.com
Merck profit more than doubles, raises outlook 7:06 a.m. Oct. 27, 2015 - MarketWatch.com
Bristol-Myers shares up 3.6% in premarket trade 6:20 a.m. Oct. 27, 2015 - Ciara Linnane
Bristol-Myers revenue buoyed by cancer drug 6:02 a.m. Oct. 27, 2015 - MarketWatch.com
Apple clashes with energy to save earnings season 7:00 a.m. Oct. 25, 2015 - Wallace Witkowski
Five Prime's stock rockets 57% premarket after licensing deal with Bristol-Myers 7:19 a.m. Oct. 15, 2015 - Tomi Kilgore
Healthcare ratings roundup 50 min ago - Seeking Alpha
Bristol-Myers Squibb (BMY) Earnings Report: Q4 2015 Conference Call Transcript 7:45 a.m. Today - TheStreet.com
Bristol-Myers Squibb's (BMY) CEO Giovanni Caforio on Q4 2015 Results - Earnings Call Transcript 4:40 p.m. Jan. 28, 2016 - Seeking Alpha
'The Market Doesn't Know Where It's Headed' 4:02 p.m. Jan. 28, 2016 - TheStreet.com
Stocks Back Near Highs in Unsettled Session 2:23 p.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Revenue Rises 1% 1:12 p.m. Jan. 28, 2016 - The Wall Street Journal Interactive Edition
Expanded uses of Bristol-Myers Squibb's HCV med Daklinza cleared in Europe 12:59 p.m. Jan. 28, 2016 - Seeking Alpha
Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish 11:20 a.m. Jan. 28, 2016 - benzinga.com
Stocks Back to Positive as Energy Trumps Health Care 11:16 a.m. Jan. 28, 2016 - TheStreet.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Unusual Social Activity Stock 10:53 a.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance 10:12 a.m. Jan. 28, 2016 - Zacks.com
Bristol-Myers' Opdivo successful in late-stage study in head and neck cancer 9:43 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues 8:13 a.m. Jan. 28, 2016 - Zacks.com
Short Sellers Become More Selective on Major Pharma 7:59 a.m. Jan. 28, 2016 - 247WallSt.com
Bristol-Myers Q4 product sales up 19%; non-GAAP EPS down 17%; net loss of $138M 7:25 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance 6:54 a.m. Jan. 28, 2016 - benzinga.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Post-Market Leader Stock 5:55 p.m. Jan. 27, 2016 - TheStreet.com
Notable earnings before Thursday’s open 5:30 p.m. Jan. 27, 2016 - Seeking Alpha
Bristol-Myers Squibb (BMY) Closed Down as Analysts Expect Earnings Decline 4:06 p.m. Jan. 27, 2016 - TheStreet.com
Lilly’s Valuation Multiples Have Followed the Industry’s Trend 1:20 p.m. Jan. 22, 2016 - MarketRealist.com
Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion forInvestigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy 7:48 a.m. Today - BusinessWire - BZX
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV 12:41 p.m. Jan. 28, 2016 - BusinessWire - BZX
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early 6:59 a.m. Jan. 28, 2016 - BusinessWire - BZX
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer 7:02 a.m. Jan. 27, 2016 - BusinessWire - BZX
Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma 8:00 a.m. Jan. 25, 2016 - BusinessWire - BZX
REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:59 a.m. Jan. 25, 2016 - BusinessWire - BZX
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:36 p.m. Jan. 23, 2016 - BusinessWire - BZX
Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 4:52 p.m. Jan. 20, 2016 - PR Newswire - PRF
Cancer Immunotherapy: Payer Insight 3:41 p.m. Jan. 20, 2016 - PR Newswire - PRF
CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone 8:01 a.m. Jan. 20, 2016 - GlobeNewswire
MOLOGEN AG: First combination trial with MGN1703and a checkpoint inhibitor in collaboration with MD Anderson 4:09 a.m. Jan. 19, 2016 - BusinessWire - BZX
SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents 8:02 a.m. Jan. 11, 2016 - Marketwired
Dual Therapeutics Announces Oncology Strategic Collaboration With Bristol-Myers Squibb 8:00 a.m. Jan. 8, 2016 - Marketwired
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3:39 p.m. Jan. 7, 2016 - PR Newswire - PRF
Insights on Immuno-Oncology Drug Development and the Field’s True Potential 6:00 a.m. Jan. 6, 2016 - BusinessWire - BZX
Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020 4:39 p.m. Jan. 5, 2016 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 10:00 a.m. Jan. 5, 2016 - BusinessWire - BZX
Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Outlook Stable 2:17 p.m. Dec. 23, 2015 - BusinessWire - BZX
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin)in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma 8:00 a.m. Dec. 23, 2015 - BusinessWire - BZX
Global Psoriatic Arthritis Market 2015-2019 4:47 p.m. Dec. 22, 2015 - PR Newswire - PRF
Bristol-Myers guidance tops estimates 7:06 a.m. Jan. 28, 2016 - MarketWatch.com
Apple, Amazon headline crucial week for Wall Street quarterly results 9:30 a.m. Jan. 23, 2016 - Wallace Witkowski
10 biotech stocks to buy at ‘silly’ cheap prices 10:10 a.m. Jan. 16, 2016 - Michael Brush
Shire agrees to buy Baxalta for $32 billion 8:49 a.m. Jan. 11, 2016 - MarketWatch.com
GlaxoSmithKline buys Bristol-Myers HIV assets 4:33 a.m. Dec. 18, 2015 - MarketWatch.com
GlaxoSmithKline to buy Bristol-Myers's HIV assets 3:21 a.m. Dec. 18, 2015 - MarketWatch.com
Samsung's bet on biotech is test for heir apparent 5:37 p.m. Dec. 17, 2015 - MarketWatch.com
5 stocks to watch 12:18 p.m. Dec. 16, 2015 - The Trading Deck
Charting the S&P 500’s impending golden cross 11:05 a.m. Dec. 9, 2015 - Michael Ashbaugh
S&P 500 will creep up to 2,200 in 2016, J.P. Morgan says 7:01 a.m. Dec. 7, 2015 - Sara Sjolin
Bristol-Myers Squibb upgraded to buy from neutral at Guggenheim 12:04 p.m. Dec. 2, 2015 - Tomi Kilgore
Merck, J&J and Lilly shares climb after upgrades at Barclays 10:14 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers Squibb stock price target raised to $70 from $55 at Barclays 9:44 a.m. Dec. 1, 2015 - Tomi Kilgore
Bristol-Myers to buy Cardioxyl Pharmaceuticals 8:11 a.m. Nov. 2, 2015 - Ciara Linnane
Merck eyes acquisitions amid slump in biotech 12:12 p.m. Oct. 27, 2015 - MarketWatch.com
Merck profit more than doubles, raises outlook 7:06 a.m. Oct. 27, 2015 - MarketWatch.com
Bristol-Myers shares up 3.6% in premarket trade 6:20 a.m. Oct. 27, 2015 - Ciara Linnane
Bristol-Myers revenue buoyed by cancer drug 6:02 a.m. Oct. 27, 2015 - MarketWatch.com
Apple clashes with energy to save earnings season 7:00 a.m. Oct. 25, 2015 - Wallace Witkowski
Five Prime's stock rockets 57% premarket after licensing deal with Bristol-Myers 7:19 a.m. Oct. 15, 2015 - Tomi Kilgore
Healthcare ratings roundup 50 min ago - Seeking Alpha
Bristol-Myers Squibb (BMY) Earnings Report: Q4 2015 Conference Call Transcript 7:45 a.m. Today - TheStreet.com
Bristol-Myers Squibb's (BMY) CEO Giovanni Caforio on Q4 2015 Results - Earnings Call Transcript 4:40 p.m. Jan. 28, 2016 - Seeking Alpha
'The Market Doesn't Know Where It's Headed' 4:02 p.m. Jan. 28, 2016 - TheStreet.com
Stocks Back Near Highs in Unsettled Session 2:23 p.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Revenue Rises 1% 1:12 p.m. Jan. 28, 2016 - The Wall Street Journal Interactive Edition
Expanded uses of Bristol-Myers Squibb's HCV med Daklinza cleared in Europe 12:59 p.m. Jan. 28, 2016 - Seeking Alpha
Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish 11:20 a.m. Jan. 28, 2016 - benzinga.com
Stocks Back to Positive as Energy Trumps Health Care 11:16 a.m. Jan. 28, 2016 - TheStreet.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Unusual Social Activity Stock 10:53 a.m. Jan. 28, 2016 - TheStreet.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance 10:12 a.m. Jan. 28, 2016 - Zacks.com
Bristol-Myers' Opdivo successful in late-stage study in head and neck cancer 9:43 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues 8:13 a.m. Jan. 28, 2016 - Zacks.com
Short Sellers Become More Selective on Major Pharma 7:59 a.m. Jan. 28, 2016 - 247WallSt.com
Bristol-Myers Q4 product sales up 19%; non-GAAP EPS down 17%; net loss of $138M 7:25 a.m. Jan. 28, 2016 - Seeking Alpha
Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance 6:54 a.m. Jan. 28, 2016 - benzinga.com
Trade-Ideas: Bristol-Myers Squibb Company (BMY) Is Today's Post-Market Leader Stock 5:55 p.m. Jan. 27, 2016 - TheStreet.com
Notable earnings before Thursday’s open 5:30 p.m. Jan. 27, 2016 - Seeking Alpha
Bristol-Myers Squibb (BMY) Closed Down as Analysts Expect Earnings Decline 4:06 p.m. Jan. 27, 2016 - TheStreet.com
Lilly’s Valuation Multiples Have Followed the Industry’s Trend 1:20 p.m. Jan. 22, 2016 - MarketRealist.com
Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion forInvestigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy 7:48 a.m. Today - BusinessWire - BZX
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV 12:41 p.m. Jan. 28, 2016 - BusinessWire - BZX
CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early 6:59 a.m. Jan. 28, 2016 - BusinessWire - BZX
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer 7:02 a.m. Jan. 27, 2016 - BusinessWire - BZX
Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma 8:00 a.m. Jan. 25, 2016 - BusinessWire - BZX
REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:59 a.m. Jan. 25, 2016 - BusinessWire - BZX
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 6:36 p.m. Jan. 23, 2016 - BusinessWire - BZX
Glioblastoma Multiforme Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 4:52 p.m. Jan. 20, 2016 - PR Newswire - PRF
Cancer Immunotherapy: Payer Insight 3:41 p.m. Jan. 20, 2016 - PR Newswire - PRF
CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone 8:01 a.m. Jan. 20, 2016 - GlobeNewswire
MOLOGEN AG: First combination trial with MGN1703and a checkpoint inhibitor in collaboration with MD Anderson 4:09 a.m. Jan. 19, 2016 - BusinessWire - BZX
SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents 8:02 a.m. Jan. 11, 2016 - Marketwired
Dual Therapeutics Announces Oncology Strategic Collaboration With Bristol-Myers Squibb 8:00 a.m. Jan. 8, 2016 - Marketwired
Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3:39 p.m. Jan. 7, 2016 - PR Newswire - PRF
Insights on Immuno-Oncology Drug Development and the Field’s True Potential 6:00 a.m. Jan. 6, 2016 - BusinessWire - BZX
Pharmacovigilance Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020 4:39 p.m. Jan. 5, 2016 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 10:00 a.m. Jan. 5, 2016 - BusinessWire - BZX
Fitch Affirms Bristol-Myers Squibb's IDR at 'A-'; Outlook Stable 2:17 p.m. Dec. 23, 2015 - BusinessWire - BZX
Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin)in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma 8:00 a.m. Dec. 23, 2015 - BusinessWire - BZX
Global Psoriatic Arthritis Market 2015-2019 4:47 p.m. Dec. 22, 2015 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼